• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2025-2026
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
  • About
    • GDPR
  • Contact

European Union’s Horizon 2020 Program Funding Underwrites Second-Generation Zika Vaccine Candidate Development: Themis Bioscience and ZIKAVAX Consortium Announce Initiation of Phase 1 Zika Vaccine Trial

October 1, 2019 By admin Leave a Comment

Themis Bioscience announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur. It was initially developed by Institut Pasteur as part of the ZIKAVAX consortium, coordinated by the European Vaccine Initiative (EVI) and including Themis and the Commissariat à l’énergie atomique et aux énergies alternatives (CEA). The four-year collaborative project covers pre-clinical and clinical development and is funded under the European Union’s Horizon 2020 Research and Innovation Program (H2020 grant agreement No 732432) with an overall budget of €5 million. The Phase 1 program and further development will be run by Themis and this first trial will evaluate the safety and immunogenicity of the candidate in healthy volunteers.

“Zika remains a global health burden with no existing vaccines, a situation exacerbated by the ongoing increase of the geographical areas exposed to the virus,” said Erich Tauber, MD, CEO of Themis Bioscience. “Together with the ZIKAVAX consortium, we have applied the immune modulation potential of our measles vector approach as well as our growing clinical development expertise to provide an urgently needed Zika vaccine. Our long-standing collaborative partnership with the Institut Pasteur has been fundamental in developing this and a number of other innovative vaccine candidates, the first of which has been validated through our Phase 3-ready Chikungunya vaccine.”

Dr Nicola Viebig, Chief Scientific Officer of EVI added: “EVI´s mission to accelerate the development of vaccines for global health crucially depends on bringing together the right partners to leverage synergies. The ZIKAVAX is a good demonstration of these efforts. Based on the in vitro and in vivo data we have gathered within the collaboration, we believe that Themis’ measles vector platform provides a promising approach for developing a safe and efficacious Zika vaccine, which we will further investigate in this clinical study.”

The observer-blinded, randomized trial will investigate the safety and tolerability of the novel Zika vaccine formulation in 48 healthy volunteers. The vaccine will be administered by intra-muscular injection in two different dose levels. Secondary objectives will include optimal dose-finding, immunogenicity and long-term safety evaluation, as well as cell-mediated immunity specific to the Zika antigen.

This is the second Zika program based on Themis’ measles vector platform to enter the clinic. The first Themis-developed Zika program was funded through an InnovateUK grant and clinical evaluation is ongoing. Themis’ lead program is a Phase 3-ready Chikungunya vaccine. The company’s pipeline includes additional earlier-staged vaccines and immuno-oncology development programs. Themis holds an exclusive license from the Institut Pasteur for its measles vector technology.

About Zika
Zika virus is a mosquito-born infectious disease that causes a mild illness in healthy adults, however, Zika virus infection during pregnancy can cause infants to be born with microcephaly. The first association of Zika infection and microcephaly were reported in 2015 in Brazil. Since that time, outbreaks and evidence of transmission have been documented throughout the world with a total of 86 countries and territories currently reporting evidence of mosquito-transmitted Zika infection.

About Themis
Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the Company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches. Initially focused on preventing infectious diseases, Themis has demonstrated the potential of its versatile platform through the rapid and successful completion of Phase 2 and near-term entry into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading venture capital firms, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and commercial manufacturing capabilities to diseases with high market potential both alone and for its partners. For more information, visit http://www.themisbio.com.

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Adobe Introduces LLM Optimizer to Help Brands Navigate the Generative AI Shift
  • Why Visa and Mastercard Stocks Slipped After the Stablecoin News
  • iOS 26: The Most Personal, Intelligent, and Private iPhone Experience Yet
  • Postman Unveils Agentic AI Tooling to Operationalize API-Driven Intelligence
  • AM Batteries Opens New Facility in Billerica to Advance U.S. Battery Supply Chain
  • Meibel Secures $7 Million to Revolutionize AI Runtime Management
  • Tailor Raises $14 Million to Redefine ERP for Modern Businesses with Composable Architecture
  • Intel Unveils New GPUs and AI Accelerators at Computex 2025
  • Unlocking Critical Minerals: USGS Invites States to Turn Mine Waste into Treasure
  • Blacksmith Reimagines Continuous Integration with AI-Optimized Infrastructure

Media Partners

  • Market Analysis
  • Cybersecurity Market
China’s Strategic Shift to RISC-V: Market Implications and Growth Prospects
Understanding Transfer Pricing: A Key Component of Multinational Business Operations
A Comprehensive Tour of Project Management Tools and Integration Platforms
Implementing Odoo ERP in a Small Manufacturing Enterprise: Costs and Considerations
Economic Optimism Meets Uncertainty: Blue Chip Indicators Highlight Post-Election Fiscal Concerns and AI’s Looming Impact
The Future of Connectivity: Insights from Ericsson’s November 2024 Mobility Report
Platinum Market Faces Sustained Deficit Amidst Strong Demand and Constrained Supply
Breaking Beijing’s Grip: U.S. and Australia Unite Against China’s Rare Earth Monopoly
Global AI-Powered Accounting and Audit Services Market Analysis 2023-2030: Growth, Trends, and Forecast
The Re-Emergence of PHP
Passwork Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Enterprise Security
Halo Security Honored with 2025 MSP Today Product of the Year Award
Cloudflare Log Explorer: A Unified Security and Performance Lens Within the Dashboard
The Rising Tide: AI and Cybersecurity Challenges Loom Large for CISOs
Arsen Launches AI-Powered Vishing Simulation to Help Organizations Combat Voice Phishing at Scale
Cyera Raises $540M to Cement Its Role as AI’s Data Security Backbone
ZeroRISC Secures $10M to Build Transparent, Secure Supply Chains
Cisco Fuses AI Security Into the Network Fabric: A Unified Vision for the Agentic Era
Guardz Raises $56M Series B to Scale AI-Native Cybersecurity Platform for MSPs and SMBs
Horizon3.ai’s $100M Bet on Autonomous Security

Media Partners

  • Market Research Media
  • Technology Conferences
The Rise of Headless Content Frameworks in Distributed Media Projects
Developing Web Projects: From Concept to Launch
The Rise of APS-C Cameras: A Professional Renaissance in Photography
Market Brief: Disruption in Spanish Orange Supply Chain and Strategic Response by UK Retailers
Global AI-Powered Movie Scenario Market Analysis 2023-2030: Growth, Trends, and Forecast
Market Research Report: US Government Cybersecurity Market in 2024
Market Research Report: Global Advertising Revenue Projections and Trends in the Entertainment & Media Industry
Social Media: The Rise of Formulaic Content
Netflix’s Creative Decline: The Rise of Formulaic Content
The Transformation of Media: Navigating the Waning Allure of Social Platforms
Apple Announces WWDC25, June 9 to 13, 2025
Adobe Summit 2025, March 17-20, Las Vegas
Embedded World 2025, from 11 to 13 March 2025 in Nuremberg
SATELLITE 2025: Uniting the Global Satellite and Space Communities
The milestone 10th edition of Chatbot Summit on March 31 – April 1, 2025, The Ritz-Carlton, Berlin
Snowflake Summit 2025, scheduled for June 2-5, 2025, in San Francisco
The NVIDIA GPU Technology Conference (GTC) 2025 is set to take place from March 17 to 21 at the San Jose McEnery Convention Center in San Jose, California
The Taipei Nangang Exhibition Center is set to host COMPUTEX 2025 from May 20 to May 23
The Mobile World Congress (MWC 2025) will kick off from March 3 to 6 in Barcelona, Spain
IOT Solutions World Congress 2025: Forging the Future of Industrial Innovation

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains